The epidemiology of multidrug-resistant organisms in persons diagnosed with cancer in Norway, 2008-2018: expanding surveillance using existing laboratory and register data
We described the incidence of MDROs and resistance proportion in Enterobacterales from 6 months prior to the person's first cancer diagnosis and up to 3 years after. The cohort included 322,005 persons, of which 0.3% (878) were diagnosed with notifiable MDROs. Peak incidence rates per 100,000 person-years were 60.9 for MRSA, 97.2 for V/LRE, and 6.8 for CP-GNB. The proportion of 3GCR-E in Enterobacterales in blood or urine cultures at OUH was 6% (746/12,534). Despite overall low MDRO incidence, there was an unfavourable trend in the incidence and resistance proportion of Gram-negative bacteria. To address this, there is a n...
Source: Cancer Control - November 18, 2023 Category: Cancer & Oncology Authors: Anders Skyrud Danielsen Petter Elstr øm Hanne-Merete Eriksen-Volle Solveig Hofvind David W Eyre Oliver Kacelnik J ørgen Vildershøj Bjørnholt Source Type: research
The epidemiology of multidrug-resistant organisms in persons diagnosed with cancer in Norway, 2008 –2018: expanding surveillance using existing laboratory and register data
We described the incidence of MDROs and resistance proportion in Enterobacterales from 6 months prior to the person’s first cancer diagnosis and up to 3 years after. The cohort included 322,005 persons, of which 0.3% (878) were diagnosed with notifiable MDROs. Peak incidence rates per 100,000 person-years were 60.9 for MRSA, 97.2 for V/LRE, and 6.8 for CP-GNB. The proportion of 3GC R-E in Enterobacterales in blood or urine cultures at OUH was 6% (746/12,534). Despite overall low MDRO incidence, there was an unfavourable trend in the incidence and resistance proportion of Gram-negative bacteria. To address this, there ...
Source: European Journal of Clinical Microbiology and Infectious Diseases - November 18, 2023 Category: Microbiology Source Type: research
Synergistic properties of linezolid against Enterococcus spp. isolates: a systematic review from in vitro studies
ConclusionOur study reported overall limited synergistic in vitro properties of linezolid with other antibiotics when tested againstEnterococcus spp. The clinical choice of linezolid in combination with other antibiotics should be guided by reasoned empiric therapy in the suspicion of a polymicrobial infection or targeted therapy on microbiological results, rather than on an intended synergistic effect of the linezolid-based combination. (Source: European Journal of Clinical Microbiology and Infectious Diseases)
Source: European Journal of Clinical Microbiology and Infectious Diseases - November 17, 2023 Category: Microbiology Source Type: research
Molecules, Vol. 28, Pages 7630: The Synergistic Activity of Rhamnolipid Combined with Linezolid against Linezolid-Resistant Enterococcus faecium
This study aimed to investigate the activity of linezolid in combination with the rhamnolipids against Enterococcus faecium. Here, we determined that the rhamnolipids could enhance the efficacy of linezolid against enterococci infections by a checkerboard MIC assay, a time–kill assay, a combined disk test, an anti-biofilm assay, molecular simulation dynamics, and mouse infection models. We identified that the combination of rhamnolipids and linezolid restored the linezolid sensitivity. Anti-biofilm experiments show that our new scheme can effectively inhibit biofilm generation. The mouse infection model demon...
Source: Molecules - November 16, 2023 Category: Chemistry Authors: Qingru Chang Huinan Chen Yifan Li Hai Li Zaixing Yang Jiankai Zeng Ping Zhang Junwei Ge Mingchun Gao Tags: Article Source Type: research
A preclinical model of TB meningitis to determine drug penetration and activity at the sites of disease
Antimicrob Agents Chemother. 2023 Nov 15:e0067123. doi: 10.1128/aac.00671-23. Online ahead of print.ABSTRACTTuberculosis meningitis (TBM) is essentially treated with the first-line regimen used against pulmonary tuberculosis, with a prolonged continuation phase. However, clinical outcomes are poor in comparison, for reasons that are only partially understood, highlighting the need for improved preclinical tools to measure drug distribution and activity at the site of disease. A predictive animal model of TBM would also be of great value to prioritize promising drug regimens to be tested in clinical trials, given the health...
Source: Antimicrobial Agents and Chemotherapy - November 15, 2023 Category: Microbiology Authors: Faye Lanni Rosleine Antilus Sainte Mark Hansen Paul Parigi Firat Kaya Katherine LoMauro Bernard Siow Robert J Wilkinson Sean Wasserman Brendan K Podell Martin Gengenbacher V éronique Dartois Source Type: research
Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis
Antimicrob Agents Chemother. 2023 Nov 15:e0078923. doi: 10.1128/aac.00789-23. Online ahead of print.ABSTRACTContezolid is a new oxazolidinone with in vitro and in vivo activity against Mycobacterium tuberculosis comparable to that of linezolid. Pre-clinical and clinical safety studies suggest it may be less toxic than linezolid, making contezolid a potential candidate to replace linezolid in the treatment of drug-resistant tuberculosis. We evaluated the dose-ranging activity of contezolid, alone and in combination with bedaquiline and pretomanid, and compared it with linezolid at similar doses, in an established BALB/c mou...
Source: Antimicrobial Agents and Chemotherapy - November 15, 2023 Category: Microbiology Authors: Deepak Almeida Si-Yang Li Jin Lee Barry Hafkin Khisimuzi Mdluli Nader Fotouhi Eric L Nuermberger Source Type: research
A preclinical model of TB meningitis to determine drug penetration and activity at the sites of disease
Antimicrob Agents Chemother. 2023 Nov 15:e0067123. doi: 10.1128/aac.00671-23. Online ahead of print.ABSTRACTTuberculosis meningitis (TBM) is essentially treated with the first-line regimen used against pulmonary tuberculosis, with a prolonged continuation phase. However, clinical outcomes are poor in comparison, for reasons that are only partially understood, highlighting the need for improved preclinical tools to measure drug distribution and activity at the site of disease. A predictive animal model of TBM would also be of great value to prioritize promising drug regimens to be tested in clinical trials, given the health...
Source: Antimicrobial Agents and Chemotherapy - November 15, 2023 Category: Microbiology Authors: Faye Lanni Rosleine Antilus Sainte Mark Hansen Paul Parigi Firat Kaya Katherine LoMauro Bernard Siow Robert J Wilkinson Sean Wasserman Brendan K Podell Martin Gengenbacher V éronique Dartois Source Type: research
Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis
Antimicrob Agents Chemother. 2023 Nov 15:e0078923. doi: 10.1128/aac.00789-23. Online ahead of print.ABSTRACTContezolid is a new oxazolidinone with in vitro and in vivo activity against Mycobacterium tuberculosis comparable to that of linezolid. Pre-clinical and clinical safety studies suggest it may be less toxic than linezolid, making contezolid a potential candidate to replace linezolid in the treatment of drug-resistant tuberculosis. We evaluated the dose-ranging activity of contezolid, alone and in combination with bedaquiline and pretomanid, and compared it with linezolid at similar doses, in an established BALB/c mou...
Source: Antimicrobial Agents and Chemotherapy - November 15, 2023 Category: Microbiology Authors: Deepak Almeida Si-Yang Li Jin Lee Barry Hafkin Khisimuzi Mdluli Nader Fotouhi Eric L Nuermberger Source Type: research
A preclinical model of TB meningitis to determine drug penetration and activity at the sites of disease
Antimicrob Agents Chemother. 2023 Nov 15:e0067123. doi: 10.1128/aac.00671-23. Online ahead of print.ABSTRACTTuberculosis meningitis (TBM) is essentially treated with the first-line regimen used against pulmonary tuberculosis, with a prolonged continuation phase. However, clinical outcomes are poor in comparison, for reasons that are only partially understood, highlighting the need for improved preclinical tools to measure drug distribution and activity at the site of disease. A predictive animal model of TBM would also be of great value to prioritize promising drug regimens to be tested in clinical trials, given the health...
Source: Antimicrobial Agents and Chemotherapy - November 15, 2023 Category: Microbiology Authors: Faye Lanni Rosleine Antilus Sainte Mark Hansen Paul Parigi Firat Kaya Katherine LoMauro Bernard Siow Robert J Wilkinson Sean Wasserman Brendan K Podell Martin Gengenbacher V éronique Dartois Source Type: research
Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis
Antimicrob Agents Chemother. 2023 Nov 15:e0078923. doi: 10.1128/aac.00789-23. Online ahead of print.ABSTRACTContezolid is a new oxazolidinone with in vitro and in vivo activity against Mycobacterium tuberculosis comparable to that of linezolid. Pre-clinical and clinical safety studies suggest it may be less toxic than linezolid, making contezolid a potential candidate to replace linezolid in the treatment of drug-resistant tuberculosis. We evaluated the dose-ranging activity of contezolid, alone and in combination with bedaquiline and pretomanid, and compared it with linezolid at similar doses, in an established BALB/c mou...
Source: Antimicrobial Agents and Chemotherapy - November 15, 2023 Category: Microbiology Authors: Deepak Almeida Si-Yang Li Jin Lee Barry Hafkin Khisimuzi Mdluli Nader Fotouhi Eric L Nuermberger Source Type: research
Theoretical study of the interaction between the antibiotic linezolid and the active site of the 50S ribosomal subunit of the bacterium Haloarcula marismortui
Chirality. 2023 Nov 14. doi: 10.1002/chir.23629. Online ahead of print.ABSTRACTFirst antibiotic in the oxazolidinone class, linezolid fights gram-positive multiresistant bacteria by inhibiting protein synthesis through its interaction with the 50S subunit of the functional bacterial ribosome. For its antimicrobial action, it is necessary that its chiral carbon located in the oxazolidinone ring is in the S-conformation. Computational calculation at time-dependent density functional theory methodology, ultraviolet-visible (UV-Vis), and electronic circular dichroism spectra was obtained for noncomplexed and complexed forms of...
Source: Chirality - November 14, 2023 Category: Molecular Biology Authors: Giulia Saneti Grandini Nelson Henrique Morgon Aguinaldo Robinson de Souza Source Type: research
Theoretical study of the interaction between the antibiotic linezolid and the active site of the 50S ribosomal subunit of the bacterium Haloarcula marismortui
Chirality. 2023 Nov 14. doi: 10.1002/chir.23629. Online ahead of print.ABSTRACTFirst antibiotic in the oxazolidinone class, linezolid fights gram-positive multiresistant bacteria by inhibiting protein synthesis through its interaction with the 50S subunit of the functional bacterial ribosome. For its antimicrobial action, it is necessary that its chiral carbon located in the oxazolidinone ring is in the S-conformation. Computational calculation at time-dependent density functional theory methodology, ultraviolet-visible (UV-Vis), and electronic circular dichroism spectra was obtained for noncomplexed and complexed forms of...
Source: Chirality - November 14, 2023 Category: Molecular Biology Authors: Giulia Saneti Grandini Nelson Henrique Morgon Aguinaldo Robinson de Souza Source Type: research
Theoretical study of the interaction between the antibiotic linezolid and the active site of the 50S ribosomal subunit of the bacterium Haloarcula marismortui
Chirality. 2023 Nov 14. doi: 10.1002/chir.23629. Online ahead of print.ABSTRACTFirst antibiotic in the oxazolidinone class, linezolid fights gram-positive multiresistant bacteria by inhibiting protein synthesis through its interaction with the 50S subunit of the functional bacterial ribosome. For its antimicrobial action, it is necessary that its chiral carbon located in the oxazolidinone ring is in the S-conformation. Computational calculation at time-dependent density functional theory methodology, ultraviolet-visible (UV-Vis), and electronic circular dichroism spectra was obtained for noncomplexed and complexed forms of...
Source: Chirality - November 14, 2023 Category: Molecular Biology Authors: Giulia Saneti Grandini Nelson Henrique Morgon Aguinaldo Robinson de Souza Source Type: research
Theoretical study of the interaction between the antibiotic linezolid and the active site of the 50S ribosomal subunit of the bacterium Haloarcula marismortui
Chirality. 2023 Nov 14. doi: 10.1002/chir.23629. Online ahead of print.ABSTRACTFirst antibiotic in the oxazolidinone class, linezolid fights gram-positive multiresistant bacteria by inhibiting protein synthesis through its interaction with the 50S subunit of the functional bacterial ribosome. For its antimicrobial action, it is necessary that its chiral carbon located in the oxazolidinone ring is in the S-conformation. Computational calculation at time-dependent density functional theory methodology, ultraviolet-visible (UV-Vis), and electronic circular dichroism spectra was obtained for noncomplexed and complexed forms of...
Source: Chirality - November 14, 2023 Category: Molecular Biology Authors: Giulia Saneti Grandini Nelson Henrique Morgon Aguinaldo Robinson de Souza Source Type: research
Advancing Diagnosis and Treatment in People Living with HIV and Tuberculosis Meningitis
AbstractPurpose of reviewTuberculous meningitis (TBM) is the most severe form of tuberculosis. Inadequate diagnostic testing and treatment regimens adapted from pulmonary tuberculosis without consideration of the unique nature of TBM are among the potential drivers. This review focuses on the progress being made in relation to both diagnosis and treatment of TBM, emphasizing promising future directions.Recent findingsThe molecular assay GeneXpert MTB/Rif Ultra has improved sensitivity but has inadequate negative predictive value to “rule-out” TBM. Evaluations of tests focused on the host response and bacterial componen...
Source: Current HIV/AIDS Reports - November 10, 2023 Category: Infectious Diseases Source Type: research
